Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 4,000 Shares of Stock
bluebird bio, Inc. (NASDAQ:BLUE) insider David Davidson sold 4,000 shares of bluebird bio stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $131.31, for a total value of $525,240.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
David Davidson also recently made the following trade(s):
- On Tuesday, August 1st, David Davidson sold 3,000 shares of bluebird bio stock. The shares were sold at an average price of $92.37, for a total transaction of $277,110.00.
- On Friday, July 7th, David Davidson sold 1,200 shares of bluebird bio stock. The stock was sold at an average price of $100.49, for a total transaction of $120,588.00.
Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up 1.45% on Wednesday, reaching $129.40. The company had a trading volume of 660,697 shares. The stock’s market cap is $5.90 billion. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $143.50. The stock has a 50-day moving average price of $118.73 and a 200-day moving average price of $100.09.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. During the same quarter in the prior year, the business earned ($1.59) EPS. The firm’s revenue for the quarter was up 977.4% compared to the same quarter last year. Analysts predict that bluebird bio, Inc. will post ($6.77) earnings per share for the current fiscal year.
A number of equities analysts have issued reports on the stock. Cowen and Company reaffirmed an “outperform” rating on shares of bluebird bio in a research note on Thursday, August 31st. Wells Fargo & Company reissued an “outperform” rating and issued a $158.00 price target (up previously from $134.00) on shares of bluebird bio in a research note on Tuesday, September 5th. Wedbush restated an “outperform” rating and issued a $135.00 price target (up from $121.00) on shares of bluebird bio in a research report on Friday, September 1st. BTIG Research cut bluebird bio from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $37.05 to $108.25 in a research note on Friday, June 30th. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $109.61.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLUE. Quantitative Investment Management LLC boosted its holdings in shares of bluebird bio by 1,193.8% in the 2nd quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock worth $11,009,000 after buying an additional 96,700 shares during the last quarter. State of Wisconsin Investment Board bought a new position in bluebird bio during the second quarter valued at about $3,257,000. Winfield Associates Inc. grew its position in bluebird bio by 6.1% during the second quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after buying an additional 162 shares during the period. OMERS ADMINISTRATION Corp bought a new position in bluebird bio during the second quarter valued at about $1,061,000. Finally, Alliancebernstein L.P. grew its position in bluebird bio by 50.1% during the first quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock valued at $7,805,000 after buying an additional 28,640 shares during the period.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.